Intradermal study of a new local anaesthetic agent aptocaine.
In  a double-blind trial in 28 human volunteers, a new local anaesthetic agent, aptocaine, was compared intradermally at 1, 2 and 3% concentrations with lignocaine 2% and bupivacaine 0.5%. In a second trial in 27 subjects, 1% aptocaine was compared with mepivacaine and prilocaine, both 1, 2 and 3%. In terms of activity as determined by area of anaesthesia, and of duration of action, aptocaine was similar to mepivacaine and more active and long-lasting than lignocaine and prilocaine. By this route aptocaine also appeared longer-lasting than bupivacaine. Duration of action was unaffected by concentration. Aptocaine had marked vasoconstrictor activity, which was maximal at 1%. These local anaesthetic properties suggest that aptocaine merits clinical trials, especially in dentistry.
D000328:Adult; D000779:Anesthetics, Local / Q000494:pharmacology; D001808:Blood Vessels / Q000187:drug effects; D002045:Bupivacaine; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007271:Injections, Intradermal; D008012:Lidocaine; D008297:Male; D008619:Mepivacaine; D008875:Middle Aged; D011318:Prilocaine; D011759:Pyrrolidines / Q000494:pharmacology; D013997:Time Factors; D014052:Toluidines / Q000494:pharmacology
D000779:Anesthetics, Local; D011759:Pyrrolidines; D014052:Toluidines; D011318:Prilocaine; C012187:aptocaine; D008012:Lidocaine; D008619:Mepivacaine; D002045:Bupivacaine